Peapod Lane Capital LLC Acquires Shares of 562,620 Kronos Bio, Inc. (NASDAQ:KRON)

Peapod Lane Capital LLC bought a new stake in Kronos Bio, Inc. (NASDAQ:KRON) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 562,620 shares of the company’s stock, valued at approximately $534,000. Peapod Lane Capital LLC owned 0.93% of Kronos Bio as of its most recent SEC filing.

Separately, Deltec Asset Management LLC purchased a new position in shares of Kronos Bio in the fourth quarter valued at approximately $190,000. 64.09% of the stock is currently owned by institutional investors.

Kronos Bio Trading Up 0.2 %

KRON stock opened at $0.97 on Thursday. The firm has a 50-day moving average of $0.99 and a two-hundred day moving average of $0.98. Kronos Bio, Inc. has a 12 month low of $0.69 and a 12 month high of $1.60. The company has a market cap of $58.54 million, a price-to-earnings ratio of -0.68 and a beta of 1.80.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. TD Cowen cut Kronos Bio from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th. Piper Sandler cut shares of Kronos Bio from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $6.00 to $1.00 in a research note on Thursday, November 14th.

Kronos Bio Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.